Marino Stram & Associates LLC boosted its position in Novartis AG (NYSE:NVS – Get Rating) by 5.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,505 shares of the company’s stock after purchasing an additional 246 shares during the quarter. Marino Stram & Associates LLC’s holdings in Novartis were worth $381,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. BNP Paribas Arbitrage SA increased its holdings in Novartis by 35.0% in the 4th quarter. BNP Paribas Arbitrage SA now owns 6,985 shares of the company’s stock worth $611,000 after purchasing an additional 1,811 shares in the last quarter. PEAK6 Investments LLC boosted its holdings in Novartis by 7.0% in the fourth quarter. PEAK6 Investments LLC now owns 3,989 shares of the company’s stock worth $349,000 after acquiring an additional 262 shares in the last quarter. Gamco Investors INC. ET AL bought a new position in Novartis in the fourth quarter worth approximately $235,000. Mutual Advisors LLC boosted its holdings in Novartis by 4.4% in the fourth quarter. Mutual Advisors LLC now owns 12,020 shares of the company’s stock worth $1,051,000 after acquiring an additional 507 shares in the last quarter. Finally, Blair William & Co. IL boosted its holdings in Novartis by 11.4% in the fourth quarter. Blair William & Co. IL now owns 101,049 shares of the company’s stock worth $8,839,000 after acquiring an additional 10,304 shares in the last quarter. 9.14% of the stock is currently owned by institutional investors.
Novartis Price Performance
NYSE:NVS opened at $77.14 on Friday. The stock has a fifty day moving average of $83.51 and a 200 day moving average of $85.71. Novartis AG has a 52-week low of $76.26 and a 52-week high of $94.26. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.13 and a current ratio of 1.38. The firm has a market capitalization of $170.68 billion, a price-to-earnings ratio of 7.54, a P/E/G ratio of 2.19 and a beta of 0.53.
Analyst Ratings Changes
NVS has been the subject of several analyst reports. Credit Suisse Group downgraded Novartis from a “neutral” rating to an “underperform” rating in a research note on Thursday, September 15th. Morgan Stanley lowered their price objective on Novartis from CHF 97 to CHF 88 in a research note on Thursday, September 8th. Oppenheimer downgraded Novartis from an “outperform” rating to a “market perform” rating in a research report on Friday, June 3rd. JPMorgan Chase & Co. increased their price target on Novartis from CHF 80 to CHF 81 and gave the company an “underweight” rating in a research report on Wednesday, July 20th. Finally, Berenberg Bank downgraded Novartis from a “buy” rating to a “hold” rating in a research report on Wednesday, September 14th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $87.00.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- 2 Semiconductor Stocks To Watch For Reversals
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.